Pharma Industrial India - Professional magazine for pharma industry suppliers and lab technology

NEWS ABOUT >

Biotechnology

Clean Rooms

Clinical Trials

Consultants

Digitalization

Drug Discovery & Development

Engineering

Global Pharma

Industrial talks

Ingredients

Lab Equipment

Logistics & Distribution

Manufacturing

Market

Outsourcing

Packaging

Quality / GMP

Regulation

Safety

Last edition

All magazines
Subscribe to our magazine

News about " immunomodulatory drug"

Bristol Myers Squibb Reports Positive Phase 2 Results for Arlo-cel in Relapsed/Refractory Multiple Myeloma

$Bristol Myers Squibb Reports Positive Phase 2 Results for Arlo-cel in Relapsed/Refractory Multiple Myeloma$

Bristol Myers Squibb’s arlo-cel demonstrated statistically significant and clinically meaningful responses in patients with quadruple-class exposed relapsed and refractory multiple myeloma.

Immunomodulatory Drug | 09/09/2026 | By News Bureau | 106

Innovent's Tri-Specific Antibody IBI3003 Secures FDA Fast Track Status for Relapsed/Refractory Multiple Myeloma

$Innovent's Tri-Specific Antibody IBI3003 Secures FDA Fast Track Status for Relapsed/Refractory Multiple Myeloma$

Innovent Biologics’ tri-specific antibody IBI3003 has received FDA Fast Track Designation for heavily pretreated relapsed or refractory multiple myeloma, supported by promising early clinical efficacy and safety data.

Immunomodulatory Drug | 27/01/2026 | By News Bureau | 341

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members